{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:44:04Z","timestamp":1781588644966,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":3202,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1038\/sj.mt.6300344","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T09:41:19Z","timestamp":1196761279000},"page":"203-209","source":"Crossref","is-referenced-by-count":42,"title":["Rapid\/Sustained Anti-anthrax Passive Immunity Mediated by Co-administration of Ad\/AAV"],"prefix":"10.1016","volume":"16","author":[{"given":"Bishnu P","family":"De","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil R","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald G","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/sj.mt.6300344_bib1","series-title":"Harrison's Principles of Internal Medicine","first-page":"1279","article-title":"Microbial bioterrorism","author":"Lane","year":"2005"},{"key":"10.1038\/sj.mt.6300344_bib2","first-page":"1","article-title":"Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001","volume":"50","author":"Rotz","year":"2001","journal-title":"MMWR Recomm Rep"},{"key":"10.1038\/sj.mt.6300344_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2144\/03341dd01","article-title":"Adeno-associated virus vectors for therapeutic gene transfer","volume":"34","author":"Stilwell","year":"2003","journal-title":"Biotechniques"},{"key":"10.1038\/sj.mt.6300344_bib4","series-title":"Gene Therapy: Therapeutic Mechanisms and Strategies","first-page":"17","article-title":"Adenovirus vectors for gene therapy","author":"Hackett","year":"2004"},{"key":"10.1038\/sj.mt.6300344_bib5","first-page":"335","article-title":"Anthrax: clinical features, pathogenesis, and potential biological warfare threat","volume":"20","author":"Friedlander","year":"2000","journal-title":"Curr Clin Top Infect Dis"},{"key":"10.1038\/sj.mt.6300344_bib6","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002: updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA"},{"key":"10.1038\/sj.mt.6300344_bib7","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3201\/eid1006.020738","article-title":"Airborne infection with Bacillus anthracis \u2014from mills to mail","volume":"10","author":"Fennelly","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1038\/sj.mt.6300344_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","article-title":"Anthrax toxin","volume":"19","author":"Collier","year":"2003","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1038\/sj.mt.6300344_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/n35101999","article-title":"Identification of the cellular receptor for anthrax toxin","volume":"414","author":"Bradley","year":"2001","journal-title":"Nature"},{"key":"10.1038\/sj.mt.6300344_bib10","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1073\/pnas.0431098100","article-title":"Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor","volume":"100","author":"Scobie","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/sj.mt.6300344_bib11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/IAI.63.1.82-87.1995","article-title":"Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases","volume":"63","author":"Gordon","year":"1995","journal-title":"Infect Immun"},{"key":"10.1038\/sj.mt.6300344_bib12","doi-asserted-by":"crossref","first-page":"20607","DOI":"10.1016\/S0021-9258(17)32036-7","article-title":"Anthrax protective antigen forms oligomers during intoxication of mammalian cells","volume":"269","author":"Milne","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1038\/sj.mt.6300344_bib13","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1073\/pnas.062160399","article-title":"Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen","volume":"99","author":"Cunningham","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/sj.mt.6300344_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20061891","article-title":"Manipulation of host signalling pathways by anthrax toxins","volume":"402","author":"Turk","year":"2007","journal-title":"Biochem J"},{"key":"10.1038\/sj.mt.6300344_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0168-1656(95)00092-5","article-title":"Development of novel vaccines against anthrax in man","volume":"44","author":"Stepanov","year":"1996","journal-title":"J Biotechnol"},{"key":"10.1038\/sj.mt.6300344_bib16","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.44.6.1766-1766.2000","article-title":"In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne","volume":"44","author":"Choe","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1038\/sj.mt.6300344_bib17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","article-title":"Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques","volume":"16","author":"Ivins","year":"1998","journal-title":"Vaccine"},{"key":"10.1038\/sj.mt.6300344_bib18","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0264-410X(98)00023-1","article-title":"The effectiveness and safety of vaccines against human anthrax: a systematic review","volume":"16","author":"Demicheli","year":"1998","journal-title":"Vaccine"},{"key":"10.1038\/sj.mt.6300344_bib19","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"key":"10.1038\/sj.mt.6300344_bib20","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"key":"10.1038\/sj.mt.6300344_bib21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"key":"10.1038\/sj.mt.6300344_bib22","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1016\/j.vaccine.2007.01.056","article-title":"Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine","volume":"25","author":"Grunow","year":"2007","journal-title":"Vaccine"},{"key":"10.1038\/sj.mt.6300344_bib23","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1128\/IAI.65.12.5171-5175.1997","article-title":"Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs","volume":"65","author":"Little","year":"1997","journal-title":"Infect Immun"},{"key":"10.1038\/sj.mt.6300344_bib24","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1016\/S0264-410X(01)00197-9","article-title":"Passive transfer of protection against. Bacillus anthracis infection in a murine model","volume":"19","author":"Beedham","year":"2001","journal-title":"Vaccine"},{"key":"10.1038\/sj.mt.6300344_bib25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/IAI.70.2.544-550.2002","article-title":"Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization","volume":"70","author":"Kobiler","year":"2002","journal-title":"Infect Immun"},{"key":"10.1038\/sj.mt.6300344_bib26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/IAI.73.2.795-802.2005","article-title":"A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge","volume":"73","author":"Mohamed","year":"2005","journal-title":"Infect Immun"},{"key":"10.1038\/sj.mt.6300344_bib27","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nbt891","article-title":"Human antibodies from immunized donors are protective against anthrax toxin In vivo","volume":"21","author":"Wild","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1038\/sj.mt.6300344_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-8518-2-5","article-title":"Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed","volume":"2","author":"Sawada-Hirai","year":"2004","journal-title":"J Immune Based Ther Vaccines"},{"key":"10.1038\/sj.mt.6300344_bib29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/IAI.74.2.1016-1024.2006","article-title":"Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax","volume":"74","author":"Peterson","year":"2006","journal-title":"Infect Immun"},{"key":"10.1038\/sj.mt.6300344_bib30","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1128\/IAI.00150-06","article-title":"A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1","volume":"74","author":"Rivera","year":"2006","journal-title":"Infect Immun"},{"key":"10.1038\/sj.mt.6300344_bib31","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1128\/IAI.00712-06","article-title":"Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity","volume":"74","author":"Vitale","year":"2006","journal-title":"Infect Immun"},{"key":"10.1038\/sj.mt.6300344_bib32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/430708","article-title":"A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers","volume":"41","author":"Subramanian","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1038\/sj.mt.6300344_bib33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1006\/viro.1997.8695","article-title":"Baculovirus expression of a human G2-specific, neutralizing IgG monoclonal antibody to Puumala virus","volume":"235","author":"Liang","year":"1997","journal-title":"Virology"},{"key":"10.1038\/sj.mt.6300344_bib34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.cgt.7700376","article-title":"Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth","volume":"8","author":"BenAmmar-Ceccoli","year":"2001","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/sj.mt.6300344_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0022-1759(01)00353-2","article-title":"High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector","volume":"252","author":"Morimoto","year":"2001","journal-title":"J Immunol Methods"},{"key":"10.1038\/sj.mt.6300344_bib36","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.1128\/JVI.76.17.8769-8775.2002","article-title":"Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer","volume":"76","author":"Lewis","year":"2002","journal-title":"J Virol"},{"key":"10.1038\/sj.mt.6300344_bib37","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1089\/10430340260185111","article-title":"High In vivo production of a model monoclonal antibody on adenoviral gene transfer","volume":"13","author":"Noel","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1038\/sj.mt.6300344_bib38","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nbt1087","article-title":"Stable antibody expression at therapeutic levels using the 2A peptide","volume":"23","author":"Fang","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1038\/sj.mt.6300344_bib39","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1158\/1078-0432.CCR-06-0746","article-title":"Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers","volume":"12","author":"Jiang","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/sj.mt.6300344_bib40","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.mt.6300142","article-title":"An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies In vivo","volume":"15","author":"Fang","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/sj.mt.6300344_bib41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymthe.2004.10.018","article-title":"Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody","volume":"11","author":"Kasuya","year":"2005","journal-title":"Mol Ther"},{"key":"10.1038\/sj.mt.6300344_bib42","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nbt0602-597","article-title":"Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity","volume":"20","author":"Maynard","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1038\/sj.mt.6300344_bib43","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1128\/MCB.8.3.1103","article-title":"Cap-independent translation of poliovirus mRNA is conferred by sequence elements within the 5\u2032 noncoding region","volume":"8","author":"Pelletier","year":"1988","journal-title":"Mol Cell Biol"},{"key":"10.1038\/sj.mt.6300344_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0092-8674(92)90213-V","article-title":"In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium","volume":"68","author":"Rosenfeld","year":"1992","journal-title":"Cell"},{"key":"10.1038\/sj.mt.6300344_bib45","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1128\/JVI.70.11.7498-7509.1996","article-title":"Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy","volume":"70","author":"Mittereder","year":"1996","journal-title":"J Virol"},{"key":"10.1038\/sj.mt.6300344_bib46","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.72.3.2224-2232.1998","article-title":"Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus","volume":"72","author":"Xiao","year":"1998","journal-title":"J Virol"},{"key":"10.1038\/sj.mt.6300344_bib47","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JVI.76.2.791-801.2002","article-title":"Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity","volume":"76","author":"Rabinowitz","year":"2002","journal-title":"J Virol"},{"key":"10.1038\/sj.mt.6300344_bib48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ymthe.2005.09.003","article-title":"High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses","volume":"13","author":"De","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/sj.mt.6300344_bib49","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1128\/JCM.29.7.1439-1446.1991","article-title":"Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay","volume":"29","author":"Plikaytis","year":"1991","journal-title":"J Clin Microbiol"},{"key":"10.1038\/sj.mt.6300344_bib50","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1089\/104303403322542310","article-title":"Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen","volume":"14","author":"Tan","year":"2003","journal-title":"Hum Gene Ther"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616313818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616313818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T20:48:27Z","timestamp":1630270107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616313818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S1525001616313818"],"URL":"https:\/\/doi.org\/10.1038\/sj.mt.6300344","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}